EMA Authorised: Maapliv (glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine) — Recordati Rare Diseases

View source ↗

Summary

EMA authorised Maapliv for Maple Syrup Urine Disease, an amino-acid based product developed for an orphan indication by Recordati Rare Diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Maple Syrup Urine Disease

Drugs mentioned

• Maapliv

Snippet

Status: Authorised. Therapeutic area: Maple Syrup Urine Disease. MAH: Recordati Rare Diseases. Decision date: 28/07/2025. Orphan medicine